Questionnaire

1. The ADA recommends that patients should be referred to a nephrologist when eGFR is:

2. SGLT-2 inhibition is now considered standard-of-care for renal and cardiovascular protection in patients with kidney disease, irrespective of the
presence of diabetes:

3. Factors that drive progression of CVD in patients with CKD and T2DM include:

4. For the treatment of CKD and T2DM, guideline-recommended agents with proven cardiovascular and kidney benefits include:

5. CKD is defined as abnormalities in kidney structure or function that have implications for health and are present for longer than:

6. The CREDENCE trial demonstrated that despite RAS and SGLT-2 inhibition, 11% of patients with T2DM and advanced CKD experienced CKD
progression or cardiovascular death within:

7. In patients with advancing CKD and T2DM, the kidney may present with:

8. Overactivation of the MR gives rise to:

9. Compared with placebo in the FIDELIO-DKD trial, treatment-emergent adverse events associated with finerenone were:

10. Life expectancy reductions are greater in women than in men for those with early CKD, those with diabetes and those with both early CKD and T2DM:

11. TGF-β levels do not correlate with albuminuria severity in patients with T2DM:

12. The DAPA-CKD and EMPA-KIDNEY trials of SGLT-2 inhibition in patients with CKD demonstrated significant improvements in renal outcomes for
participants:

13. Cardiovascular mortality risk increases with:

14. In human tissues, the MR receptor is expressed in:

15. Finerenone is a: